NET Alliance Issues New E-Book on Neuroendocrine Cancer
May 12, 2014
NETrospectives, a new e-book produced by The NET Alliance, is "a journey through the past and a vision for the future of neuroendocrine cancer." The e-book presents patients, patient advocates, and physicians talking about the diagnoses of these rare diseases, imaging techniques and treatment options, raising the standard of care, and connecting with others in the carcinoid/neuroendocrine tumor (NET) community. Read more
Luncheon with the Experts in New York City
April 13, 2014
Join carcinoid and neuroendocrine tumor patients on Sunday, May 4, 2014 for a unique opportunity to have lunch with three medical experts. Share your experiences with others who have similar concerns and hear from the physicians on issues ranging from NET cancer treatments and surgery to carcinoid heart disease to follow-up testing and new developments. Read more
AJCC Names Chair of Neuroendocrine Tumors Expert Panel
April 7, 2014
Eugene A. Woltering, MD, The James D. Rives Professor of Surgery and Neuroscience and Director of Surgical Research at LSU Health Sciences Center in Kenner, Louisiana, has been selected to serve as Chair of the Neuroendocrine Tumors Expert Panel for the American Joint Committee on Cancer’s (AJCC) Cancer Staging System, 8th Edition. Read more
BerriHealth Supports NET Cancer Research
March 25, 2014
BerriHealth, a leader in providing high-quality black raspberry powder for clinical trials and directly to consumers online, has donated a portion of their 2013 sales to New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS), led by Dr. Eugene Woltering. In 2014, BerriHealth is working to expand their support for cancer research. Read more
NIH Clinical Trial
March 7, 2014
Learn more about a unique opportunity for carcinoid and NET cancer patients to have a state-of-the-art scan: the Gallium-68 (GA-68) DOTATATE PET/CT scan. Click Here
First Global NET Cancer Patient Survey
March 3, 2014
Please help the Carcinoid Cancer Foundation in collaboration with the Caring for Carcinoid Foundation – both members of the International Neuroendocrine Cancer Alliance (INCA) -- increase awareness and education about NET worldwide by completing the first ever global survey of carcinoid and neuroendocrine tumor (NET) cancer patients! Read more
The online survey closed on May 31, 2014. Thank you to the nearly 2,000 NET patients around the world who completed the survey!!!
Now Online -- New Jersey Carcinoid Cancer NETwork Conference Videos
January 20, 2014
Videos from the New Jersey Carcinoid Cancer NETwork Conference, held on November 2, 2013, are now available online. The guest speakers for the conference were carcinoid/neuroendocrine tumor specialists Dr. Richard R.P. Warner, Dr. Eric H. Liu, and Dr. Yi-Zarn Wang and endocrinologist Dr. Justina Deitz. Click here to read more and see the videos.
You can make a real difference in the lives of those facing carcinoid cancer and other neuroendocrine tumors by supporting The Carcinoid Cancer Foundation (CCF). Your contributions help fund our work of increasing awareness and educating the general public and healthcare professionals about carcinoid and related neuroendocrine cancers; providing support for patients and their loved ones; and serving as advocates for the carcinoid/NET (neuroendocrine tumor community). These programs lead towards our ultimate goals of early detection, a possible cure, and improving the quality of life for cancer survivors and their families.
Every donation counts -- help bring us one step closer to our goals.
Endurance Competitive Rider and Goblet Cell Carcinoid Cancer Survivor Takes on New International Challenge
November 26, 2013
Battling goblet cell carcinoid cancer has not deterred Monica Grundmann from pursuing her dream as an endurance rider with her Morab stallion, Excalibur Legend. Next month Monica will represent Eastern Canada in the North American Team Challenge 160-km, a 24-hour Endurance Race in Florida, competing against Western Canada, the U.S. and Mexico. ““I have always and will continue to live each day as if it is my last - saying and doing the maximum,” says Monica. “Obviously my personal goals regarding my beloved stallion, his competitions and his legacy, are paramount for me. Together, he and I have achieved much more than I ever could have dreamed and I am extremely grateful for being blessed to have him.” Read more about Monica’s amazing accomplishments and her journey with a rare cancer.
FDA Grants Orphan Drug Designation to Gallium-68 DOTATOC for Neuroendocrine Tumor Management
November 22, 2013
BREAKING NEWS – The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Read more from the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET support group in California. From the FDA, here’s information about how drugs are designated as an orphan product, read more.